BC Extra | Aug 9, 2019
Financial News

ORIC raises $55M to fund trials in drug-resistant cancers

With a $55 million series D round and recent hires from Ignyta and Genentech, ORIC believes it has the money and the team to advance multiple drug-resistant cancer therapies through clinical studies. ORIC Pharmaceuticals Inc....
BC Extra | May 1, 2019
Company News

April 30 Company Quick Takes: Merck, G1, Pfizer, Amgen and more

Merck sales rise in China Merck & Co. Inc. (NYSE:MRK) said product sales in China were $725 million for 1Q19, up 67% on an ex-exchange basis from 1Q18 and driven by products in its vaccines...
BioCentury | Apr 6, 2019
Finance

Everybody up

Biotech stocks were off to a strong start in 1Q19, with 71% of companies tracked by BioCentury seeing market cap growth in the quarter. Across all market cap bands, biotechs saw a median gain of...
BC Extra | Mar 28, 2019
Politics & Policy

China lists 30 more overseas drugs eligible for Priority Review

China’s Drug Evaluation Center posted a second batch of drugs already approved in the U.S., EU or Japan that could be eligible for Priority Review in China. Fourteen of the 30 drugs on the list...
BioCentury | Mar 1, 2019
Product Development

Prostate cancer disrupted

Two imminent disruptions threaten to upend the treatment landscape for prostate cancer, changing who gets anti-androgen therapies and ushering in the first new MOAs in decades. The launch of generic abiraterone means next generation anti-androgens...
BC Week In Review | Feb 1, 2019
Clinical News

J&J's Erleada meets in Phase III for castration-sensitive prostate cancer

Janssen Pharmaceuticals Inc. said a preplanned analysis by an IDMC showed that Erleada apalutamide met the dual primary endpoints in the Phase III TITAN trial to treat metastatic castration-sensitive prostate cancer (CSPC). The Johnson &...
BC Extra | Jan 30, 2019
Clinical News

J&J's Erleada meets in Phase III for castration-sensitive prostate cancer

Janssen Pharmaceuticals Inc. said a preplanned analysis by an IDMC showed that Erleada apalutamide met the dual primary endpoints in the Phase III TITAN trial to treat metastatic castration-sensitive prostate cancer (CSPC). The Johnson &...
BC Extra | Jan 8, 2019
Politics & Policy

CHMP recommendations of new active substances up in 2018

EMA said on Friday that the agency's CHMP recommended for approval 42 new active substances in 2018, up seven from 35 in 2017 and its highest total since at least 2013. The recommendations include 11...
BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BC Week In Review | Nov 30, 2018
Clinical News

CHMP backs first all-oral sleeping sickness treatment, extensions for Blincyto, Opdivo-Yervoy combo

EMA's CHMP recommended a basket of approvals and label extensions on Nov. 16, including the first all-oral treatment for African trypanosomiasis (sleeping sickness). The agency issued no negative opinions in its monthly roundup. The agency...
Items per page:
1 - 10 of 51